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There are Challenges in statistically modelling immune responses to longitudinal HIV viral
load exposure as a function of covariates. We define Bayesian Markov Chain Monte Carlo
mixed effects models to incorporate priors and examine the effect of different distributional
assumptions. We prospectively fit these models to an as-yet-unpublished data from the
Tshwane District Hospital HIV treatment clinic in South Africa, to determine if cumulative log
viral load, an indicator of long-term viral exposure, is a valid predictor of immune response.
Methods
Models are defined, to express ‘slope’, i.e. mean annual increase in CD4 counts, and
‘asymptote’, i.e. the odds of having a CD4 count�500 cells/μL during antiretroviral treat-
ment, as a function of covariates and random-effects. We compare the effect of using infor-
mative versus non-informative prior distributions on model parameters. Models with cubic
splines or Skew-normal distributions are also compared using the conditional Deviance
Information Criterion.
Results
The data of 750 patients are analyzed. Overall, models adjusting for cumulative log viral
load provide a significantly better fit than those that do not. An increase in cumulative log
viral load is associated with a decrease in CD4 count slope (19.6 cells/μL (95% credible
interval: 28.26, 10.93)) and a reduction in the odds of achieving a CD4 counts�500 cells/μL
(0.42 (95% CI: 0.236, 0.730)) during 5 years of therapy. Using informative priors improves
the cumulative log viral load estimate, and a skew-normal distribution for the random-inter-
cept and measurement error results is a better fit compared to using classical Gaussian
distributions.
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Discussion
We demonstrate in an unpublished South African cohort that cumulative log viral load is a
strong and significant predictor of both CD4 count slope and asymptote. We argue that
Bayesian methods should be used more frequently for such data, given their flexibility to
incorporate prior information and non-Gaussian distributions.
Introduction
The rollout of effective combination antiretroviral therapy (ART) has markedly improved the
survival of sub-Saharan African (SSA) Human Immunodeficiency Virus (HIV)-infected popu-
lations [1]. However, resource-limited settings are characterised by the late initiation of ART
[2] and limited ongoing immunologic or virologic monitoring [3,4]. The difficulty of recover-
ing CD4 count increases with due to decreasing thymic CD4+ T-cell production [5], and also
depends on direct and indirect effects of chronic viral replication [6]. Further, in part due to
its recent roll-out in SSA and limited monitoring, the long-term immunological consequences
of ART remain incompletely understood [7–9].
There are challenges in the statistical modelling of the relationship of HIV viral load (VL)
to CD4 counts. As a result, mechanistic models, which make particular assumptions regarding
underlying biological processes, have commonly been used for this purpose [10,11]. A previ-
ous review of statistical models of immune response to ART in SSA revealed an immense
diversity in the methodologies employed [12]. However, particularly two main types of statisti-
cal models of immune response following ART initiation were identified. Namely, those quan-
tifying, ‘Slope’ of change in CD4 counts within a specified time after initiation, and
‘Asymptote’, which quantify achieving or not a predefined minimal ‘normal’ threshold of CD4
count within a specified time. There was also a sub-type of the above, namely ‘Time-to’ achiev-
ing a particular threshold [12]. In this study, we investigate slope and asymptote models.
Cumulative VL (cVL) is a readily definable indicator of long-term in vivo exposure to
detectable virus [13] and positively associated with an increase in mortality [13]. Few studies
have investigated the association of cVL with immune response to ART. Marconi et al [14]
used the summated area under a patient’s ‘raw’ VL curve which was then subsequently log-
transformed (cVL1), as a predictor of immune response in the data of a North American
cohort. However, as previously discussed, the methods they employed have statistical weak-
nesses and the relevance of their findings to resource-constrained SSA settings may be limited
[13]. In this study, we use cumulative log VL (cVL2), i.e. the summation of the area under the
initially log-transformed VL curve above the limit of detection.
Previous statistical models have usually assumed normality for CD4 count distributions
despite studies demonstrating that this is not justified [12,15–17]. This may have been due to
frequentist modelling software requiring this assumption. Bayesian methods, in combination
with Markov Chain Monte Carlo (MCMC) computational techniques, allow the use of alterna-
tives to Gaussian distributions, the incorporation of prior information and considerable flexi-
bility with respect to estimation. For a general overview of the Bayesian methodology refer to
Lesaffre and Lawson [18] and Gelman et al. [19].
To encourage model reproducibility and standardization, which has been historically lack-
ing, we employ slope and asymptote statistical models based on a consensus of those previ-
ously systematically reviewed [12]. Bayesian MCMC mixed-effects methods are used to
incorporate priors and examine the effect of different distributional assumptions. We then
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prospectively apply these models to the data of an as-yet-unpublished SSA HIV treatment
cohort and determine if cVL2 is a valid predictor of immune response.
Methods
Ethics statement
This study was approved by the Research Ethics Committee of the Faculty of Health Sciences
at the University of Pretoria (13/2010) and the Tshwane Metsweding Region Research Com-
mittee (TMREC 2011/05) to retrospectively capture, and analyse routinely collected data at the
Tshwane District Hospital in Gauteng, South Africa. The Research Ethics Committee waived
the need for informed consent since the data was de-identified during capture.
Study setting and patient population
The comprehensive demographic and long-term treatment data of the first, consecutive, 963
patients older than 18 years of age who presented for ART at the Tshwane District Hospital in
Gauteng, South Africa during 2004 and 2005 were selected for analysis. All patients started
ART after 2004 as part of the South African national HIV treatment plan and were treated
according to the National Department of Health HIV guidelines (2004) operative at the time,
i.e. eligibility for ART was CD4 <200 cells/μL or WHO stage 4 disease regardless of CD4
count. Treatment was initiated using a standardized triple-drug regimen consisting of two
nucleoside reverse transcriptase inhibitors, mostly d4T and 3TC, and one non-nucleoside
reverse transcriptase inhibitor, either NVP or EFV. CD4 and HIV-1 VL monitoring was per-
formed at treatment initiation ‘baseline’ and then 6-monthly, according to the national proto-
col. Demographic, anthropometric, clinical, ART and 5-year longitudinal treatment response
data were collected. We excluded all second-line ART visits for all patients who were switched
to second-line therapy.
Data collection and inclusion criteria
Data was collated in Microsoft Excel spreadsheets. Of an initial 963 patients, 213 patients were
excluded as they only had a baseline visit, preventing the calculation of cVL2. Of the remaining
750 patients, 59 patients had missing data for either sex, baseline CD4 count, baseline log VL
or longitudinal CD4 counts. The Bayesian models included imputation for missing data in
both the CD4 outcomes and the covariates, during each model iteration [18]. For the ‘slope’
model the data of 750 patients was analysed. In the ‘asymptote’ model, a further 5 patients
were excluded as they had CD4 counts�500 cells/μL at baseline, leaving 745 patients, see
Figure A in S2 Appendix.
Statistical methods
Model definitions. In this study, two types of longitudinal statistical models were investi-
gated. These were defined based on a consensus from a prior systematic review [12]. The utility
of including cVL2 as a covariate was examined in both cases:
1. The ‘Slope’ model, in which the outcome was the mean annual increase in absolute CD4
count measured at 6-monthly intervals following ART initiation. In this case, the post-ART
immune trajectory was the metric of interest; and,
2. The ‘Asymptote’ model, in which the outcome was the odds of achieving a CD4 count
�500 cells/μL at any particular time during the 5 years of ART. If at any visit following
ART initiation there was a CD4 count�500 cells/μL it was coded as ‘1’, or ‘0’, if below, i.e. a
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binary outcome. In this case, achieving or not a specified ‘normal’ CD4 count threshold was
the metric of interest. Note, a 500 cells/μL threshold was chosen as it is the described lower
end of the healthy reference range of CD4 counts for the SSA population [20]. Patients
were also excluded when their baseline CD4 count was�500 cells/μL, as prior studies have
shown that when such people initiate ART they have an almost equal life expectancy to the
general population [21,22].
The lower detection limit for the VL assay used in this cohort was 50 copies/mL. However,
a value of 400 copies/mL was used in the calculation of cVL2 [13] as doing so enabled the
exclusion of smaller ‘viral blips’ (50–400 copies/mL) that are unrelated to subsequent viral
rebound and failure [23,24]. Transitory values of below 1000 copies/mL have been shown to
have no quantitative difference in estimates of opportunistic infections and mortality com-
pared to a threshold of 400 copies/mL during treatment [13].
Thus, cVL2, measured as copy-year/mL, for the i-th patient at their j-th visit is given by,
cVL2ij ¼
Pk¼j












where ti,k and Vi,k represent the time (in years) and log VL measurement of the k-th visit,
respectively. cVL2 was set to 0 at baseline. All visits where VL was missing (49% of 8250 visits
see Figure B in S2 Appendix) were excluded during estimation of cVL2. The cVL2 for patients
with missing VL intervals was estimated with a longer inter-visit duration i.e. (ti,k−ti,k−1) as
seen in Eq 1.
Variables. These included: sex (‘0’ for males and ‘1’ for females), baseline age (years),
baseline CD4 count, baseline log VL (log10 copies/mL), time on treatment (years) as per prior
model consensus [12], and cVL2 (log10 copy-year/mL) as described above (Eq 1). cVL2 coeffi-
cient was multiplied with a binary variable (0 –if the patient was lost to follow-up and 1 –if the
patient was still in care) (see model implementation in S1 Appendix).
Model structure
Also as per prior consensus [12], we used linear mixed-effects models, with random intercept
and slope on time on treatment, as these models have most often been used to study CD4
count response while on ART [25–27]. Absolute CD4 counts are known to vary within and
between patients [8,28] and CD4 measurements further apart in time were found to be less
correlated than those closely adjacent. Nash et al. 2008 [22] have demonstrated, in patients ini-
tiating ART with <200 cells/μL, that the largest gains in CD4 count were seen in the first 6
months of treatment after which it slowed down considerably. The majority (91.7%) of our
cohort had baseline CD4 counts <200 cells/μL.
We define 9 models, each with two scenarios, namely, unadjusted (i.e. without cVL2) and
adjusted (i.e. with cVL2). These are labelled as follows:
• Model 1: slope model second-degree polynomial model where errors and random effects are
normally distributed;
• Model 2: slope model where errors and random effects are normally distributed and has
cubic splines with 3 inner knots;
• Model 3: slope model where errors and random effects are normally distributed and has
cubic splines with 5 inner knots;
• Model 4: slope model where random-effects are SN distributed;
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• Model 5: slope model where measurement error and random-effects are SN distributed.
• Model 6: Asymptote model second-degree polynomial model where random effects are nor-
mally distributed;
• Model 7: Asymptote model where random effects are skew-normally distributed;
• Model 8: Asymptote model where random-effects are normally distributed with cubic splines
and 3 inner knots; and
• Model 9: Asymptote model where random-effects are normally distributed with cubic splines
and 5 inner knots.
Slope models (Eq 2) were initially defined as second-degree polynomials, i.e. a quadratic
term of time on treatment with a random intercept and slope. This was referred to as model 1
and defined as follows:
� yi ¼ xi βþ zi bi þ εi;
bi � Nð0;SbÞ; εi � Nð0; s2εImiÞ
ð2Þ
for i = (1,. . .,n) patients. The CD4 count response is given by an mi-dimensional vector,
yi ¼ ðyi1; yi2; . . . ; yimiÞ
T
, β = (β0,β1,. . .,βp)
T is a (p+1)−dimensional vector of unknown regres-
sion coefficients, xi ¼ ðxi1; xi2; . . . ; ximiÞ
T
is a (mi x(p+1)) matrix of p fixed effects, zi ¼
ðzi1; zi2; . . . ; zimiÞ
T
is a (mi x q) design matrix for the ith, q dimensional vector of random effects.
The measurement error εi ¼ ðεi1; εi2; . . . ; εimiÞ
T
is a mi−dimensional normally distributed vec-
tor with mean zero and covariance, s2εImi , and assumed to be independent of the random
effects. bi is assumed to have a bivariate Gaussian distribution with mean zero and (q x q)
covariance matrix Sb.








We also examined replacing 2nd degree polynomials with cubic B-splines with 3 inner
knots. This procedure slices the data around important time points as previously described by
Corbeau et al 2011 [29], at (1.250, 2.5, 3.751), or 5 inner knots, at (0.833, 1.666, 2.5, 3.334,
4.167), that latter of which is simply a more extreme case of the 3 inner knots. For more details,
refer to the ‘Spline models’ model 2 and model 3 in S1 Appendix.
Distributional considerations
Models such as the above assume that measurement errors and random effects are normally
distributed, meaning that responses must also be normally distributed given the covariates.
Most prior studies have assumed that CD4 count response is either Gaussian normally distrib-
uted or have applied log or square-root variable transformations to achieve normalization
[30,31]. In isolated cases, the Poisson distribution has also been applied [32]. However, the lat-
ter assumes equal mean and variance, which is invariably unjustified. In this case, these param-
eters differed dramatically, 366 cells/μL versus 56481.3 cells/μL, respectively. Further, at any
particular time during treatment, the distribution of CD4 count values are usually skewed
[33]. Thus, inferences based on using such methods might result in bias.
For this reason, in addition to the Gaussian normal, we also investigated Skew-normal (SN)
distributions. The SN distribution is an extension of the former, consisting of a Gaussian com-
ponent and a skewness component. Initially, only the random-effects were assumed to have a
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SN distribution (Eq 3), i.e. bi~SNq(0,Sb,Δb), where each ith individual has a 2-dimensional ran-
dom-effects covariance matrix, Sb. The deviation from normality is given by the skewness
part, here chosen the same for all random effects, namely Δb = diag(δ,. . .,δ). Note that for δ = 0
we obtain the Gaussian distribution. For more details, refer to [33,34].
� yi ¼ xi βþ zi bi þ εi;
bi � SNqð0;Sb;DbÞ; εi � Nð0; s2εImiÞ
ð3Þ
Thereafter, SNs were assumed for both random effects and measurement error (Eq 4).
Namely, εi � SNmið0; s
2
εImi ;DεiÞ; and random-effects, bi~SNq(0,Sb,Δb) where Dεi and Δb are
the respective skewness terms. An unknown (mix mi) skewness diagonal matrix, Dεi ¼












For more details, refer to the ‘SN models’ model 4 and model 5 in S1 Appendix
The asymptote models (Eq 5) were also initially defined as second-degree polynomials, and
the same variables used in the slope model were adjusted for. This was referred to as model 6
and defined as follows:
(
logitðπiÞ ¼ xi βþ zi bi;
bi � Nqð0;SbÞ
ð5Þ
For πij = prob(yij = 1) if CD4 count�500 cells/μL and ‘0’ otherwise for patient ‘i’ at visit ‘j’.
πi ¼ ðpi1; pi2; . . . ; pimiÞ
T
is an mi-dimensional vector, with a Bernoulli distribution. The model






A SN distribution for the random-effects (Eq 6) was also investigated, see ‘SN model’ model
7 S1 Appendix.
(
logitðπiÞ ¼ xi βþ zi bi;
bi � SNqð0;Sb;DbÞ
ð6Þ
where elements of bi are defined in the same way as those in Eq 3. Further, we also investigated
the use of cubic B-splines with 3 and 5 inner knots, as described for Eq 2, refer to ‘Spline mod-
els’ model 8 and model 9 in S1 Appendix.
Missing data imputation
In the Bayesian framework, missing data imputation uses the data augmentation algorithm
[35]. Given dataset D, with missing data MD, and parameters K, the algorithm determines,
with each iteration, plausible values by sampling MD from a conditional distribution P(MD |
D, K), and then imputes these values. It then samples K from a conditional distribution of the
posterior P(K | D, MD) [18]. For missing data on baseline CD4 count and baseline VL we esti-
mated P(MD | D, K) using multiple linear regression. For imputation of sex we used multiple
logistic regression.
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The linear regression imputation models were defined as:
� yi ¼ xi ϕþ εi;
εi � Nð0;o2Þ;
ði ¼ 1; . . . ; nÞ ð7Þ
In Eq 7 the response, CD4 count is an n-dimensional vector yi = (y1,y2,. . .,yn)T, assumed to
have a linear relationship with xi = (1,x1,x2)T an (n x 3) matrix of 2 fixed effects of sex and base-
line age. ϕT = (ϕ0,ϕ1,ϕ2) is a 3-dimensional vector of regression coefficients and ε an n×1 vec-
tor of random errors, for additional details refer to S1 Appendix.
logitðπiÞ ¼ xi ϕ; i ¼ ð1; . . . ; nÞ ð8Þ
In Eq 8, for πi = prob(yi = 1) if sex is female and ‘0’ otherwise for patient ‘i’. πi = (π1,π2,. . .,
πn)T is an mi-dimensional vector, with a Bernoulli distribution. ϕT = (ϕ0,ϕ1,ϕ2,ϕ3) a 4-dimen-
sional vector of regression coefficients and xi = (1,x1,x2,x3)T an (n x 4) matrix of 3 fixed effects
of baseline age, baseline CD4 count, and baseline log VL. Note, baseline CD4 count and base-
line log VL, which had MD, was used to impute missing sex. For this reason we used Eq 7 to
impute the MD for the first two variables, and then imputed a value for the missing sex.
Priors.
Non-informative priors: For slope of CD4 count models in Eqs 2, 3 and 4, the unknown
parameters are: fβ; sε;Dεi ; r; ϕ; θ; τε; s0; s1;Db;ϑb; γb;αg, where for those not defined in the
preceding sections, ρ is the correlation for the random-effects, τε is a vector for the scale
parameter for the imputed models, σ0 and σ1 are the respective standard deviations of the ran-
dom intercept and slope, ϑb is a vector of parameters that make up the skewness parameter for
the random effects in the SN models, γb is a vector of shape parameters for the random-effects
in the covariance matrix of the SN models, and α is a vector of coefficients on the random-
effects part in both types of SN models (i.e. Eqs 3 and 4). For more details regarding these pri-
ors, please refer to the section on priors for each of the models in S1 Appendix.
For asymptote models in Eqs 5 and 6, the unknown parameters are: {β,ρ,ϕ,θ,τε,σ0,σ1,α,Δb,
ϑb, γb}, where ρ is the correlation for the random-effects, τε is a vector for the scale parameter
for the imputed models, σ0 and σ1 are the respective standard deviations of the random inter-
cept and slope, ϑb is a vector of parameters that make up the skewness parameter for the ran-
dom effects in the SN models, γb is a vector of shape parameters for the random-effects in the
covariance matrix in the SN models and α is a vector of coefficients on the random-effects part
in of SN random-effects model. For details about these priors please refer to the section on pri-
ors for each of the models in S1 Appendix.
Vague Gaussian, uniform, inverse-gamma, and inverse-Wishart prior distributions were
used for the regression coefficients, the error variance and the covariance matrix of the ran-
dom effects, respectively.
Informative priors: For the regression coefficients of sex, baseline log VL, and polynomial
terms, the mean and variances were estimated from prior studies [25,36]. Meaning, these were
only possible for polynomial models in which the random effects had Gaussian distributions.
SN distributions were not applied in the reviewed prior studies [12]. Simple linear mixed-effect
models were generated for each of the covariates—for example, CD4 count as the outcome
adjusted for sex as the only covariate, resulting in a posterior estimate for sex (i.e. 36.17). The
change in the posterior estimates from the full model, model 1 (i.e. 24.1) to that in the simple
linear mixed-effect model (i.e. 36.17) was obtained using this method. This change was then
added (i.e. -12.04) to the historical study estimate (i.e. 35.2) [36] to get to 23.16, which was
then used as an informative prior mean for sex, see Table 1. The precision was estimated from
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the variance, s2, using the formula for the upper 95% confidence intervals (uCI):












For example, in [36] the simple regression coefficient for female-sex and the uCI were 35.2
and 66.5 respectively, with a sample size n = 459. Substituting this into Eq 10 yields s2 =
117054.8, and a precision of 8.543007E-06 (Table 1). In the asymptote models, historical stud-
ies used different CD4 count thresholds [12], meaning that informative priors were not
possible.
Data analysis
R version 3.2.2 (R Foundation for Statistical Computing, Vienna, Austria, https://cran.r-
project.org/) and OpenBUGS (http://www.openbugs.net) were used. Except for time on treat-
ment, all continuous covariates were standardized to a mean of zero and standard deviation
equal to one. Three MCMC chains were employed in both models. For the second-degree
polynomial slope models, a burn-in of 20K followed by a further 45K iterations was used. For
other variations of the slope and asymptote models, a burn-in of 80K followed by 100K itera-
tions was used. The SN random-effects slope model had 250K burn-in followed by 250K itera-
tions while that for asymptote model employed 500K burn-in followed by 500K iterations. We
ensured that the models ran until the Monte Carlo error was <5% of the posterior standard
deviation. For confirmation of convergence, the Brooks-Gelman-Rubin (BGR) diagnostic was
used.
Models were selected based on the conditional Deviance Information Criterion (cDIC)
[37]. Unless models differ by at least 5, no clear model choice can be expected. Moreover,
Quintero and Lesaffre (2018) showed that the marginal DIC (mDIC) should be chosen, based
Table 1. Estimating informative priors used for slope of CD4 count model.
Variable Model Coefficients a Informative priors
Historical study Current study (Est.) model 1 (Est.) Changeb Coef.c Variance (Var.) Precision (1/Var.)
Est. Upper CI
Female-sex [36] n = 459 35.2 66.5 36.17 24.1 -13.17 23.16 117055 8.54E-06
Baseline log10 viral load (copies/mL) [36]
n = 459
13.9 22.2 -10.09 7.5 -11.89 11.31 8231.08 1.22E-4
Time on treatment (years) [25]
n = 12946
65 69 56.18 52.3 -0.68 61.12 53919.2 1.86E-05
Time on treatment (years)-squared [25]
n = 12946
-6 -5 -22.97 -23.0 -0.27 -6.03 3369.95 2.97E-04
a list of coefficients from historical simple linear mixed-effects models as published in the respective articles (historical study) and from the same reanalysed models
using our data (current study Est.)
b obtained by subtracting current study coefficients from full model (model 1)
c obtained by adding both Change and historical study Est. columns.
https://doi.org/10.1371/journal.pone.0224723.t001
Cumulative viral load as a predictor of CD4+ T-cell response to ART using Bayesian statistical models
PLOS ONE | https://doi.org/10.1371/journal.pone.0224723 November 13, 2019 8 / 19
on the marginal specification of the linear mixed-effects model [38]. Unfortunately, there is no
software yet available to compute the mDIC in the general case considered here. Hence, we
considered only a clear model choice if the cDIC’s differ by approximately 10 [38]. Parameter
means and 95% equal-tail credible intervals (95%CI) are reported below.
Results
Descriptive results
213 patients were excluded from analysis as they only had a baseline visit. This group had
higher median baseline log VLs, i.e. 5.3 log10 copies/mL (IQR: 4.76, 5.54) vs 5.1 log10 copies/
mL (IQR: 4.64, 5.48), (p = 0.003), and were older, i.e. 39 years (IQR: 34, 47) vs 36 years (IQR:
31, 42), (p<0.001).
In the data of the 750 patients analysed, 69.6% (n = 522) were female, with a median base-
line age of 36 years (IQR: 31, 42). The median baseline CD4 count was 89 cells/μL (IQR: 43,
143) and median baseline log VL, 5.1 log10 copies/mL (IQR: 4.64, 5.48). The overall median
increase in cVL2 after 5 years on ART was 0.3 log10 copy-year/mL (IQR: 0.30, 0.43). Patients
initiated on ART with baseline CD4 count >200 cells/μL (n = 43) experienced a 278 cells/μL
median increase, starting at 261 cells/μL (IQR: 219, 298) and ending at 529 cells/μL (IQR: 420,
633) during 5-years of follow-up. Those with CD4 count 101–200 cells/μL (n = 291) at baseline
experienced a 241 cells/μL median increase during 5-years of follow-up on ART from 143
cells/μL (IQR: 120, 173) to 386 cells/μL (IQR: 253, 525). Patients with�100 cells/μL (n = 416)
at baseline experienced a 270 cells/μL median increase in CD4 count during 5-years of follow-
up on ART from 47 cells/μL (IQR: 20, 72) to 317 cells/μL (IQR: 188, 496).
Patients with baseline log VL>5 log10 copies/mL (n = 411) experienced a CD4 count
median increase of 268 cells/μL during follow-up, from 78 cells/μL (IQR: 41, 131) to 367 cells/
μL (IQR: 232, 515), while those with�5 log10 copies/mL (n = 339) had a 237 cells/μL median
increase in CD4 count from 103 cells/μL (IQR: 47, 161) to 365 cells/μL (IQR: 226, 512). The
overall median increase in cVL2 from ART start by baseline CD4 count category was 0.6 log10
copy-year/mL (IQR: 0.44, 0.82), 0.7 log10 copy-year/mL (IQR: 0.50, 0.90), and 0.7 log10 copy-
year/mL (IQR: 0.55, 1.28) for patients with baseline CD4 count>200, 101–200, and�100
cells/μL, respectively. Only 33.8% of the patients in the data used in the asymptote model ever
reached a CD4 count�500 cells/μL.
Slope models
After adjusting for sex, baseline age, baseline CD4 count, baseline log VL and time on treat-
ment an increase in cVL2 is associated with a -19.6 cells/μL (95%CI: -28.25, -10.93) mean
annual decrease in absolute CD4 counts over 5-years of follow up, Table 2. All other estimates
of the regression coefficients were associated with CD4 count response as their 95%CIs do not
include zero. The adjusted, i.e. with cVL2, model has a substantially lower cDIC compared to
the crude, i.e. without cVL2 (47480 vs 47510, respectively), Table H in S2 Appendix. The
median predicted CD4 count response, generated from the cVL2 adjusted model 1, among
patients with baseline CD4 count�100 cells/μL is lower compared to those with>200 cells/
μL, especially within the first 2 years of ART. The trend is similar but still lower compared to
those in the 101–200 cells/μL category. This is more pronounced towards the 5th year of ART,
Fig 1A. Females demonstrate a marginally higher median predicted increase in CD4 counts
than males, Fig 1B. There is no difference in median predicted CD4 count increase between
stratified groups of baseline age (�50 vs >50 years) or baseline log10 VL (�5 vs >5 copies/
mL) during follow-up, Fig 1C and 1D.
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Asymptote models
After adjusting for sex, baseline age, baseline CD4 count, time on treatment and baseline log
VL, an increase in cVL2 reduces the odds for having a CD4 count�500 cells/μL at any time
during 5 years of follow-up, i.e. 0.42 (95%CI: 0.236, 0.730), Table 3. For none of the variables,
other than baseline log VL, the 95%CI for the posterior mean odds ratio includes one. The
cVL2 adjusted compared to the unadjusted model 6 has a substantially lower cDIC (1695 versus
Table 2. Posterior means and 95% credible intervals of the regression coefficients for the slope of CD4 count models.
Parameter without cVL2 model 1 with cVL2 model 1
Estimate 95% CI Estimate 95% CI
Female-sex 24.1 (12.97, 35.29) 23.8 (12.53, 34.96)
Baseline age -6.9 (-12.06, -1.65) -6.3 (-11.57, -1.08)
Baseline CD4 count 82.4 (76.94, 83.10) 82.9 (77.4, 88.38)
Baseline log viral load 7.5 (-2.16, 12.92) 7.5 (2.03, 12.92)
Time on treatment 52.3 (45.52, 58.98) 55.7 (48.83, 62.65)
Time on treatment-squared -23.0 (-24.99, -20.93) -22.7 (-24.86, -20.78)
cumulative log viral load – – -19.6 (-28.25, -10.93)
cVL2—cumulative HIV log viral load.
https://doi.org/10.1371/journal.pone.0224723.t002
Fig 1. Predicted posterior median CD4 counts trajectory by covariate strata for the slope of CD4 count model, with 95% prediction intervals. A. baseline CD4
count (cells/μL), B. sex, C. baseline age (years), D. baseline log10 VL (copies/mL). Median predicted CD4 counts from model 1, is plotted. The red, black or blue dots
represent predicted median CD4 count at different time points, and the bars are the whiskers.
https://doi.org/10.1371/journal.pone.0224723.g001
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1716, respectively), Table H in S2 Appendix. Adjusting for cVL2 clearly provides a better fit to
the data. Except for patients whose baseline CD4 count was >200 cells/μL and 101–200 cells/
μL, the median predicted probability of having a CD4 count�500 cells/μL is always less than
0.5 throughout the 5 years of ART, Fig 2A. Females demonstrate a higher median predicted
probability of having a CD4 count�500 cells/μL compared to males, Fig 2B, especially during
the first 2.5 years of treatment. Patients with a baseline age�50 years old have similar median
predicted probabilities of a CD4 count�500 cells/μL compared to those >50 years, Fig 2C. It
seems more likely for�50-year-old patients to reach at least 0.5 probability of achieving CD4
count�500 cells/μL (at 3 years of ART) compared to those>50 years who never reach this
during 5 years of follow-up. Patients with higher baseline log10 VL,�5 copies/mL, have a simi-
lar median predicted probability compared to those with baseline log VL>5 copies/mL of hav-
ing CD4 counts�500 cells/μL for 5 years, Fig 2D.
Refinements of initial models
In the slope model, changing model structure from a second-degree polynomial to cubic
splines, model 2 and model 3, provides significantly higher cDIC’s (Table H in S2 Appendix),
indicating that the polynomial model, i.e. model 1 is a better fit. The random effects are not
convincingly normally distributed, Figure C in S2 Appendix, prompting further investigation
into SN distributions. The SN distribution of the random-effects yields a significantly lower
cDIC for both the unadjusted and adjusted, model 4, compared to Gaussian models. This is
more pronounced in the unadjusted versus adjusted in model 4 (i.e. 47270 vs 47480, respec-
tively). However, for model 5 both unadjusted and adjusted models (i.e. with SNs for both ran-
dom-effects and measurement errors) have the smallest cDIC’s. Except for the spline models,
cVL2 remains a significant covariate in determining the slope of CD4 count, Table H in S2
Appendix and Table 4.
Using informative priors
This improved estimation of covariate effects in model 1
�
. For example, the mean annual effect
of cVL2 on immune response increases from -19.6 cell/μL (95%CI: -28.25, -10.93) in model 1,
i.e. without informative priors, to -19.7 cell/μL (95%CI: -28.35, -11.10) in model 1
�
, i.e. with
informative priors. For additional details refer to Table E in S2 Appendix.
In the asymptote model, the distribution of the random-effects of the polynomial version is
visibly skewed, Figure D in S2 Appendix, implying that the use of a Gaussian normal distribu-
tion for the random effects is inappropriate. Using a SN yields a significantly lower cDIC
Table 3. Posterior mean odds ratios and 95% credible intervals of the regression coefficients for the binary longitudinal models with response: CD4 counts�500
cells/μL.
Parameter without cVL2 model 6 with cVL2 model 6
Estimate 95% CI Estimate 95% CI
Female-sex 5.85 (2.886, 11.977) 6.35 (3.019, 14.382)
Baseline age, years 0.55 (0.398, 0.749) 0.54 (0.389, 0.740)
Baseline CD4 count 2.82 (2.103, 3.811) 3.00 (2.175, 4.145)
Baseline log viral load 1.24 (0.895, 1.705) 1.26 (0.905, 1.799)
Time on treatment 3.35 (2.413, 4.457) 4.08 (3.019, 5.579)
Time on treatment—squared 0.68 (0.581, 0.814) 0.65 (0.550 0.745)
cumulative log viral load – – 0.42 (0.236, 0.730)
cVL2—cumulative HIV log viral load.
https://doi.org/10.1371/journal.pone.0224723.t003
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compared to a Gaussian distribution, model 7 = 829 vs model 6 = 1695 in the adjusted model
and in the unadjusted, model 7 = 1108 vs model 6 = 1716, Table H in S2 Appendix. The
adjusted SN model still has the lowest cDIC among all asymptote models. Overall, the SN
model has slightly smaller CIs compared to the normal random effects model, Table 5. cVL2
remains a significant covariate in the asymptote model, Table 5.
Fig 2. Predicted posterior median probability of having�500 cells/μL CD4 counts by covariate strata, with 95% prediction intervals. A) baseline CD4 count
(cells/μL), B) sex, C) Baseline age (years), D) baseline log10 viral load (copies/mL). Median predicted probability of having CD4 count�500 cells/μL from model 6. The
red, black or blue dots represent predicted probability of having CD4 count�500 cells/μL at different time points, and the bars are the whiskers.
https://doi.org/10.1371/journal.pone.0224723.g002
Table 4. The effect of changing from a Gaussian to a skew-normal on the estimated regression coefficients, with 95% credible intervals, in the slope model.
Parameter cVL2 adjusted model 1 cVL2 adjusted model 4
Estimate 95% CI Estimate 95% CI
Female-sex 23.8 (12.53, 34.96) 23.8 (12.61, 35.12)
Baseline age -6.3 (-11.57, -1.08) -6.4 (-11.61, -1.14)
Baseline CD4 count 82.9 (77.4, 88.38) 82.8 (77.36, 88.29)
Baseline log viral load 7.5 (2.03, 12.92) 7.5 (2.06, 12.91)
Time on treatment 55.7 (48.83, 62.65) 55.7 (48.72, 62.57)
Time on treatment-squared -22.7 (-24.86, -20.78) -22.8 (-24.84, -20.78)
cumulative log viral load -19.6 (-28.25, -10.93) -19.4 (-28.12, -10.74)
cVL2 –cumulative HIV log10 viral load. All estimates reported as posterior mean and 95% credible intervals.
https://doi.org/10.1371/journal.pone.0224723.t004
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Discussion
Proper adherence to ART, in the absence of HIV drug resistance, is sufficient to suppress HIV
VL in plasma. When this is not achieved ongoing viral replication causes progressive depletion
of CD4+ T-cells through direct and indirect mechanisms [8,29,39]. However, the extent of
damage by a detectable VL in the short-term may not be readily apparent as CD4 counts are
inherently variable within and between people [15–17].
Using prospectively defined models on an unpublished SSA HIV treatment cohort, we
demonstrated that long-term consequences of a history of detectable VL, i.e. the cVL2 bio-
marker, on immune response while on ART. cVL2 is strongly associated with, and provides
better model fits for, both slope and asymptote CD4 count models. These combined CD4
count-VL dynamics have not previously been demonstrated in causal statistical models and
are in apparent agreement with the findings of biologically ‘mechanistic’ mathematical models
[11]. After adjusting for sex, baseline age, baseline CD4 count, baseline log10 VL and time on
treatment, each log10 copy-year/mL increase in cVL2 was associated with a decrease in slope of
CD4 counts and lower odds of having a CD4 count of�500 cells/μL while on ART. The
median probability of having a CD4 count�500 cells/μL was still< 0.5 among patients with a
baseline CD4 count�100 cells/μL after 5 years of follow-up. Having a CD4 count�500 cells/
μL while on ART was previously associated with a similar life expectancy to that in the normal
population [21]. Our findings provide evidence for increased benefits of early ART initiation,
as the probability of having a CD4 counts�500 cells/μL is then increased.
In addition to baseline log VL, increasing baseline age, associated with a reduction in the
size and functionality of the thymus [5,29], and lower baseline CD4 counts [22,40,41] are asso-
ciated with ineffective CD4 count recovery. Lawn et al. [42] have shown that late ART initia-
tors, with baseline CD4 count<200 cells/ μL, equivalent to 94% of our cohort, often take
longer than 5 years of treatment before they reach CD4 count�500 cells/μL. In our cohort
and elsewhere [22], patients with baseline CD4 count� 200 cells/μL never reached a 0.5
median predicted probability of having a CD4 count�500 cells/μL. Further, such patients are
at risk of developing suboptimal immune response, i.e. failure to reach CD4 count>350 cells/
μL after 5 years of ART [43]. Patients with>200 cells/μL at baseline experienced a decline in
the median predicted probability of having CD4 count�500 cells/μL after 3 years, Fig 2A. It is
possible that patients initiated on ART at>200 cells/μL quickly reach a CD4 count ceiling
which, according to Williams et al 2006 and Kulkarni et al 2011 is related to pre-infection and
immediate post-infection CD4 count levels [44,45]. Our findings of better CD4 count recovery
in females compared to males is consistent with prior findings [8,22,25,29,41], even though we
Table 5. The effect of changing from a normal to a skew-normal distribution on the random-effects on the regression coefficients, with 95% credible intervals, in
the asymptote model.
Parameter cVL2 adjusted model 6 cVL2 adjusted model 7
Estimate 95% CI Estimate 95% CI
Female-sex 6.35 (3.019, 14.382) 6.52 (3.004, 14.397)
Baseline age 0.54 (0.389, 0.740) 0.54 (0.386, 0.748)
Baseline CD4 count 3.00 (2.175, 4.145) 3.04 (2.235, 4.242)
Baseline log viral load 1.26 (0.905, 1.799) 1.27 (0.904, 1.785)
Time on treatment 4.08 (3.019, 5.579) 4.04 (3.034, 5.425)
Time on treatment—squared 0.65 (0.550 0.745) 0.65 (0.564, 0.746)
cumulative log viral load 0.42 (0.236, 0.730) 0.41 (0.236, 0.718)
cVL2 –cumulative HIV log10 viral load. All estimates reported as posterior odds ratios with 95% credible intervals (CI).
https://doi.org/10.1371/journal.pone.0224723.t005
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had fewer males than females a trend which is common in clinical settings in sub-Saharan
Africa [46].
Results from randomized controlled trials such as the ‘Strategies for Management of Antire-
troviral Therapy’ (SMART) [47], ‘Strategic Timing of Antiretroviral Therapy (START)’ [48]
and ‘Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa’ (TEMPRANO)
[49], indicated benefits of early initiation of ART to reduce AIDS and non-AIDS infection in
HIV patients. Currently, the World Health Organization recommendations are to initiate
ART in all newly diagnosed HIV patients, regardless of their CD4 count a diagnosis. However,
many people living with HIV are still initiated late on ART, reflected by low baseline CD4
counts [50], possibly due to programmatic bottlenecks, e.g. drug stock-outs, limited clinic
space, late diagnosis or patient decisions to defer ART. Our findings are relevant resource-lim-
ited settings in highly HIV burdened sub-Saharan Africa.
cVL2 attempts to capture cumulative HIV antigenic exposure due to detectable viral load
(>400 copies/mL) during ART. However, cVL2 estimation improves with narrower sampling
intervals [13,51]. Increasing VL sampling frequency in resource-limited settings is unrealistic
as it is expensive. Mechanistic models have shown that the HIV virus has a short half-life of
approximately 2 days [52], which implies that during ART, an HIV VL test shows the current
VL rather than a time-averaged measure across the interval or up to a few weeks before the
sampling visit. Considering this, interpreting VL tests may not be as informative as time-aver-
aged cVL2, which may be a relevant biomarker for cumulative antigenic pressure.
Our models do not adjust for duration of HIV infection prior to ART initiation as this
information was not available. This may have resulted in biased model estimates for cVL2.
However, we did control for baseline CD4 count which, although perhaps not ideal due to
inter-patient variability in the rate of CD4 decline prior to ART [53], is frequently used as a
surrogate marker for duration of infection [54]. Further, approaches for adjusting for pre-ART
VLs, as summarized in a prior study [13], may be of limited value as they are dependent on an
individual’s innate viral controlling ability. In the future, adjusting similar models with data
for HIV ‘recency’ assay results [55,56] if available, may serve as an additional indication for
duration of infection.
A Bayesian approach was helpful in that it enabled us to apply informative prior estimates
from historical models, although this was limited to only those that assume Gaussian normal-
ity [12,25,36]. Assuming normal distributions for random effects that are intrinsically not nor-
mally distributed is questionable and likely to produce biased results [57,58]. We found that
models with both SN distributions for the random-effects and measurement errors produced
substantially smaller cDIC’s, i.e. the best model fits. The predicted distributions for the ran-
dom-effects in both slope and asymptote models were observably skew, as can be seen in
Figure C in S2 Appendix and even more so in Figure D in S2 Appendix. Thus, using SN distri-
butions is likely to have improved the description of the dataset as a whole. Having said that,
the β-parameters and 95%CIs obtained after using non-informative and informative priors
were similar, likely owing to the relatively large size of the dataset [59].
The considered models all assumed that when patients have an incomplete follow-up that
either: (1) the reason for incompleteness is not related to the outcome (Missing completely at
random) or (2) could have been predicted from past history (missing at random). Of course, it
can also be that the incompleteness is related in a more complicated manner to the outcome
(missing not at random). However, there is no clear solution on how to deal with this case.
Some possible approaches are joint modelling, sensitivity analyses assuming different mecha-
nisms for the incompleteness, etc. Addressing missing not at random missingness mechanisms
thus involve a lot of extra considerations. The possible impact of this missingness mechanism
on our data will be the topic of future research.
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This study has limitations. As for most Bayesian models based on sizeable datasets, running
them was computationally intensive. Estimation of cVL2 may also have been affected by sampling
frequency, as previously alluded to [13]. VL was measured bi-annually in the current cohort; thus,
the effect of detectable VL might have excluded unmeasured viral rebounds occurring between
sampling intervals. This cohort included patients who were initiated on ART at very low median
CD4 counts, i.e. 87 cells/μL (IQR: 43, 144), and may consequently have been predisposed to poor
CD4 count responses, Fig 1, as compared to cohorts with early ART initiation in resource-rich
settings. Our results may be prone to a ‘survival’ bias as 213 patients, who were excluded from this
study because they only had a baseline visit, were older and had a higher baseline VL.
Taken together, the results of this study show promising use of the cVL2 metric to describe
CD4 count response in ART patients. Models were prospectively defined and tested on the
data of an as yet undescribed SSA HIV treatment cohort. Bayesian methods enabled the incor-
poration of prior information from historical studies. All assumptions were explicitly defined
facilitating reproducibility and standardization. In the future, quantifying the effect of viral
rebounds occurring between sampling intervals and duration of HIV infection may help
improve our understanding of the effect of cVL2.
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